PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease.
Peroxisome proliferator-activated receptor gamma (PPARgamma) is a nuclear receptor that is known to play a central role in adipocyte differentiation and insulin sensitivity. Through work in several animal models of intestinal inflammation, it is now recognized that PPARgamma also inhibits tissue injury associated with immune activation. These studies point to PPARgamma as a novel anti-inflammatory mediator with broad therapeutic potential.
Wada
K
K
Nakajima
A
A
Blumberg
R S
RS
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000378:metabolism; D002839:Chromans / Q000378:metabolism; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000378:metabolism; D003424:Crohn Disease / Q000188:drug therapy* / Q000378:metabolism; D004195:Disease Models, Animal; D007249:Inflammation / Q000378:metabolism; D007422:Intestines / Q000473:pathology; D008024:Ligands; D051379:Mice; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics / Q000378:metabolism*; D000077154:Rosiglitazone; D013844:Thiazoles / Q000378:metabolism; D045162:Thiazolidinediones; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*; D000077288:Troglitazone
D000893:Anti-Inflammatory Agents; D002839:Chromans; D008024:Ligands; D018160:Receptors, Cytoplasmic and Nuclear; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; D000077154:Rosiglitazone; D000077288:Troglitazone